Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
32.3M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
10.1M
-
Shares change
-
+10.1M
-
Total reported value, excl. options
-
$136M
-
Value change
-
+$136M
-
Number of buys
-
30
-
Price
-
$13.67
Significant Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) as of Q3 2023
31 filings reported holding DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share as of Q3 2023.
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.1M shares
of 32.3M outstanding shares and own 31.23% of the company stock.
Largest 10 shareholders include FMR LLC (2.22M shares), Fairmount Funds Management LLC (1.93M shares), 5AM Venture Management, LLC (1.47M shares), Avidity Partners Management LP (1.22M shares), VR Adviser, LLC (928K shares), TANG CAPITAL MANAGEMENT LLC (592K shares), Octagon Capital Advisors LP (480K shares), Nantahala Capital Management, LLC (337K shares), Atlas Venture Life Science Advisors, LLC (237K shares), and Alphabet Inc. (209K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.